Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03352778
Other study ID # NPC031
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 29, 2017
Est. completion date June 30, 2021

Study information

Verified date October 2021
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Irradiation of the parotid gland with subsequent long-term xerostomia is a well-recognized complication after radiotherapy for head and neck (HAN) cancers. A number of studies have shown that IMRT could minimize the radiation dose to the parotid glands and hence the risk of developing xerostomia. The benefit of IMRT has also been demonstrated in prior dosimetric and non-randomized studies in NPC patients. In 2007, the investigators have published the prospective randomized study of IMRT versus 2DRT in early stage NPC patients. In the study, IMRT had lower incidence of observer-rated severe xerostomia, higher parotid and whole saliva flow rate, than patients in 2DRT arm at 1 year after treatment. However, there was no significant difference in patient-reported outcome, i.e. subjective xerostomia scoring, between the 2 arms. The underlying reason for the incoherent findings in terms of objective and subjective xerostomia outcome remains uncertain. One of the possible explanations for this observation could be the better parotidsparing with IMRT alone may not entirely sufficient to maintain oral cavity lubrication while the other mucin-secretory salivary gland protection is also essential. Another possible explanation for the insignificant improvement in patient-reported outcome with IMRT is the short follow-up time. Gradual recovery or improvement in various quality of life parameters was not uncommonly seen several years after definitive radiotherapy for HAN cancer patients. There is much interest in studying the long term clinical outcome, especially the treatment-related complications, for the patients who had randomized and treated in the prior presented prospective study. In this study, the long term results, in particular the xerostomia rating will be assessed and compared in NPC patients who had participated in the prior reported prospective randomized study of IMRT vs 2DRT.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - The NPC patient, who had been enrolled, randomized and treated in the prior prospective randomized study of IMRT vs 2DRT. - Regular follow-up for more than five years from the end of study intervention (i.e. IMRT or 2DRT for NPC). - Patient is able to sign the study-specific informed consent. - ECOG performance status 0 or 1. - Patient is able to complete the study's questionnaire. Exclusion Criteria: - NPC patients who had not been randomized or allocated to the study intervention, even though had been enrolled in the prior reported study. - Loss of regular follow-up from the end of study intervention. - Regular follow-up for less than five years from the end of study intervention. - Patients with known recurrent or metastatic disease. - Patients with secondary malignancy occurred after completion of the previous study's treatment (i.e. radiotherapy). - Active untreated infections - Major medical or psychiatric illness

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
IMRT
66Gy by intensity-modulated radiotherapy
2DRT
66Gy by 2-dimensional radiotherapy

Locations

Country Name City State
Hong Kong The Chinese University of Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure QOL difference between 2DRT vs IMRT by EORTC QLQ-C30 core questionnaire. A 10-point difference of mean scores of QOL between groups were significant. 2 years
Primary To measure QOL difference between 2DRT vs IMRT by EORTC QLQ-H&N 35 questionnaire. A 10-point difference of mean scores of QOL between groups were significant. 2 years
Primary To measure difference in xerostomia score between 2DRT vs IMRT by using the xerostomia questionnaire (6-item xerostomia questionnaire. Johnson et al). A low score indicates worse xerostomia. 2 years
Secondary To measure the difference of the incidence of loco-regional recurrence between 2DRT vs IMRT. 2 years
Secondary To measure the difference of the overall survival and progression-free survival between 2DRT vs IMRT. 2 years
Secondary To measure the difference of numbers of 2DRT vs IMRT patients with treatment-related adverse events as assessed by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03734809 - NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer Phase 2
Recruiting NCT03158324 - Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 Phase 2
Completed NCT04945421 - IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC Phase 1
Recruiting NCT03919552 - Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT04284332 - Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC) Phase 2
Recruiting NCT05983432 - Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors Phase 1
Completed NCT03973723 - Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Active, not recruiting NCT01744587 - Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients N/A